Capricor Therapeutics (CAPR) News Today

$6.20
+0.56 (+9.93%)
(As of 05/17/2024 ET)
Capricor Therapeutics (NASDAQ:CAPR) Receives New Coverage from Analysts at Oppenheimer
Oppenheimer started coverage on Capricor Therapeutics in a research report on Friday. They set an "outperform" rating and a $14.00 price objective on the stock.
Capricor Therapeutics Inc Expected to Earn FY2024 Earnings of ($1.27) Per Share (NASDAQ:CAPR)
Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2024 EPS estimates for shares of Capricor Therapeutics in a research note issued on Tuesday, May 14th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will earn ($1
Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Lowered by StockNews.com
StockNews.com lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday.
Expert Ratings For Capricor Therapeutics
Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $25.00
LADENBURG THALM/SH SH boosted their target price on Capricor Therapeutics from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday.
Capricor Therapeutics (NASDAQ:CAPR) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday.
Here's what to expect from Capricor Therapeutics's earnings report
Capricor Therapeutics (CAPR) Set to Announce Earnings on Monday
Capricor Therapeutics (NASDAQ:CAPR) will be releasing earnings after the market closes on Monday, May 13, Zacks reports.
Capricor Therapeutics' (CAPR) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research note on Thursday.
Capricor Therapeutics Inc (CAPR)
FY2024 Earnings Estimate for Capricor Therapeutics Inc Issued By Cantor Fitzgerald (NASDAQ:CAPR)
Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Capricor Therapeutics in a research report issued on Wednesday, March 13th. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will pos
Q4 2023 Capricor Therapeutics Inc Earnings Call
Recap: Capricor Therapeutics Q4 Earnings
Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)

Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls.

Claim your free seat by clicking here now.

CAPR Media Mentions By Week

CAPR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CAPR
News Sentiment

-0.09

0.49

Average
Medical
News Sentiment

CAPR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CAPR Articles
This Week

32

2

CAPR Articles
Average Week

Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CAPR) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners